ロード中...
Pomalidomide with Dexamethasone for Treating Relapsed and Refractory Multiple Myeloma Previously Treated with Lenalidomide and Bortezomib: An Evidence Review Group Perspective of an NICE Single Technology Appraisal
The National Institute for Health and Care Excellence (NICE), as part of the institute’s single technology appraisal (STA) process, invited the manufacturer of pomalidomide (POM; Imnovid(®), Celgene) to submit evidence regarding the clinical and cost effectiveness of the drug in combination with dex...
保存先:
| 出版年: | Pharmacoeconomics |
|---|---|
| 主要な著者: | , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Springer International Publishing
2017
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5805808/ https://ncbi.nlm.nih.gov/pubmed/29086363 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40273-017-0581-6 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|